EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

BRAF Mutation Status Determines the Prognostic Value of Tumor Bilaterality in Papillary Thyroid Carcinoma: A Retrospective Cohort Study

Shitu Chen iD, Fang Chen iD, Xingyun Su iD, Jie Zhou iD, Zhendong Chen iD, Zehang Xu iD, Bingjie Sun iD, Lisong Teng iD, Weibin Wang iD

International Journal of Endocrinology · 2026-01 · 2026 (1)

DOI: 10.1155/ije/1121143 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Endocrinology, online erschienen am 28.04.2026. Verfasst von Shitu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, zju.edu.cn. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While bilaterality is a frequent characteristic of papillary thyroid carcinoma (PTC), its prognostic implications in the context of BRAF genetic heterogeneity remain undefined. This study investigates the synergistic prognostic value of tumor bilaterality and BRAF mutation status in PTC recurrence risk stratification.

Methods

We retrospectively reviewed 974 consecutive PTC patients who were surgically treated in the First Affiliated Hospital of Zhejiang University School of Medicine. Genomic DNA was extracted from fresh frozen tumor tissues. The BRAF mutation status was confirmed by Sanger sequencing. The cases were analyzed for various histologic and clinical parameters in order to determine the correlation between bilaterality and risk of recurrence in the different BRAF statuses.

Results

Overall, bilaterality was associated with larger tumor size, gross extrathyroidal extension (ETE), and lymph node metastasis. Bilateral PTCs had a higher risk for recurrence (9.8% vs. 4.9%, p = 0.014) but did not retain significance after multivariable adjustment. In BRAF‐mutant patients, bilaterality was strongly associated with aggressive features such as larger tumor size, gross ETE, and lymph node metastasis and could serve as an independent risk factor for recurrence, corresponding to an HR of 2.23 (95% CI: 1.65,4.76; p = 0.020). BRAF‐mutant patients with bilateral tumors also exhibited a high recurrence rate of 10.3%. Notably, this effect was exclusively observed in BRAF‐mutant patients. Among these patients, the combination of bilaterality and large tumor size (> 10 mm) identified the highest‐risk subgroup, with a disease‐free survival (DFS) rate of only 86%. In contrast, these associations were not observed in BRAF wild‐type patients, regardless of tumor size or laterality.

Conclusions

The current study provides initial evidence that tumor bilaterality serves as a BRAF genotype–dependent prognostic marker, revealing its synergistic effect with BRAF mutation in predicting PTC recurrence. Its prognostic value is further amplified by large tumor size, with the coexistence of bilaterality and large tumor diameter identifying a distinct high‐risk population, exclusively among BRAF‐mutant patients. Incorporating BRAF status into the assessment of patients with bilateral PTC, particularly those with larger tumors, may refine postoperative risk stratification and facilitate more tailored surveillance strategies.

Schlagwörter

Stichwörter der Autor:innen

BRAF mutationbilateralitypapillary thyroid cancerprognosis

Autor:innen und Institutionen

  • Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, zju.edu.cn.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, zju.edu.cn.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, zju.edu.cn.

ORCID-Profile: Shitu Chen, Fang Chen, Xingyun Su, Jie Zhou, Zhendong Chen, Zehang Xu, Bingjie Sun, Lisong Teng, Weibin Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, S., Chen, F., Su, X., Zhou, J., Chen, Z., Xu, Z., Sun, B., Teng, L., & Wang, W. (2026). BRAF Mutation Status Determines the Prognostic Value of Tumor Bilaterality in Papillary Thyroid Carcinoma: A Retrospective Cohort Study. International Journal of Endocrinology, 2026(1). https://doi.org/10.1155/ije/1121143

Vancouver

Chen S, Chen F, Su X, Zhou J, Chen Z, Xu Z, et al. BRAF Mutation Status Determines the Prognostic Value of Tumor Bilaterality in Papillary Thyroid Carcinoma: A Retrospective Cohort Study. International Journal of Endocrinology. 2026;2026(1). doi:10.1155/ije/1121143

BibTeX
@article{Chen2026,
  author = {Chen, Shitu and Chen, Fang and Su, Xingyun and Zhou, Jie and Chen, Zhendong and Xu, Zehang and Sun, Bingjie and Teng, Lisong and Wang, Weibin},
  title = {BRAF Mutation Status Determines the Prognostic Value of Tumor Bilaterality in Papillary Thyroid Carcinoma: A Retrospective Cohort Study},
  journal = {International Journal of Endocrinology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ije/1121143}
}
Kostenlos starten →